Rifaximin for fatty liver with metabolic issues
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests if rifaximin, a gut-targeted antibiotic, can help people with fatty liver disease who also have metabolic problems like obesity or diabetes. You need a recent fatty liver diagnosis and a liver fat level of at least 8% on an MRI scan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need a fatty liver diagnosis within the last 6 months.
- You must have at least one metabolic issue like being overweight (BMI ≥23), type 2 diabetes, or other metabolic problems (like high waist size, blood pressure, or cholesterol).
- Your liver fat must be at least 8% as measured by a special MRI scan.
- You cannot have cirrhosis or other liver diseases like viral hepatitis, and you must not be taking certain medications that affect gut bacteria or liver health unless on a stable dose for at least 24 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if rifaximin, a gut medication, can help reduce liver fat in people with metabolic fatty liver disease. It may be an option if you have at least one metabolic risk factor and a certain amount of liver fat.
This trial tests whether the antibiotic rifaximin (taken by mouth) can improve heart function in people with a type of heart failure where the heart pumps well but is still weak (HFpEF). Rifaximin might help by changing the bacteria in your gut.
This trial tests a medication called rifaximin (an antibiotic that works in the gut) to see if it reduces bloating in people with functional bowel disorders like IBS or chronic constipation. If you have stubborn bloating despite treatment, this could be a new option to help you feel better.
This study looks at how a specific gut bacteria (Ruminococcus gnavus) and the chemicals it makes are linked to a type of fatty liver disease called MAFLD. By joining, you'll help researchers understand this connection, which may lead to better treatments in the future.
This trial tests whether an oral antibiotic called rifaximin can improve symptoms during a microscopic colitis flare. It aims to see if it is safe and effective for people whose colitis was confirmed by colon biopsy.
This study tests whether a specially designed gut bacteria treatment can help people with fatty liver disease and related health issues like high blood sugar, high cholesterol, or high blood pressure. It aims to see if the treatment is safe and improves liver health.
Hear when a new Metabolic Associated Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.